好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Feasibility of Using a Smartphone Application to Evaluate Huntington Disease
Movement Disorders
P1 - Poster Session 1 (5:30 PM-6:30 PM)
10-046
To assess the feasibility of using an Android smartphone application, GEORGE®, to quantitatively measure motor features of Huntington disease (HD).
Current measures of Huntington disease are insensitive, subjective, and restricted to in-person visits. As technology becomes increasingly inexpensive, ubiquitous, and advanced, smartphones present a unique opportunity to objectively measure disease. Previous studies in the Parkinson disease population have demonstrated that smartphones effectively measure motor symptoms and correlate well with clinician assessments.

Developed at the University of Rochester, GEORGE® is the first smartphone application for HD and has the potential to distinguish between individuals with and without HD, quantify motor symptoms, and assess response to drug treatment. GEORGE® uses the smartphone’s sensors to assess chorea and balance, the screen to assess tapping speed, and the microphone to assess voice.

 

We are conducting an observational study of 40 participants: 20-25 with clinically diagnosed HD, 5-10 with prodromal HD, and 10 without a movement disorder. Participants undergo two in-clinic assessments and complete the application’s tasks three times daily for one month. Primary outcome measures include feasibility and quantitative motor data.

 
To date, 15 subjects have been enrolled, and 14 have completed the study. Six participants have manifest HD, one has prodromal HD, and seven are healthy controls. 53% of participants are women. On average, participants use the application 2.3 times daily, with no significant difference in frequency based on disease status. Data analysis is ongoing, but we have observed a significant difference in chorea score derived from the application between individuals with and without HD.
Preliminary data suggest use of a smartphone application to differentiate individuals with and without HD and measure disease features is feasible. Refinement of the interface and activities of GEORGE® could improve usability and sensitivity of data and, ideally, lay the foundation for its use in HD clinical trials.
Authors/Disclosures
Jamie L. Adams, MD (University of Rochester Medical Center)
PRESENTER 		Dr. Adams has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Adams has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Michael J. Fox Foundation. Dr. Adams has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BioSensics. The institution of Dr. Adams has received research support from NIH/NINDS. The institution of Dr. Adams has received research support from Biogen. The institution of Dr. Adams has received research support from The Michael J. Fox Foundation. The institution of Dr. Adams has received research support from Critical Path Institute. Dr. Adams has received personal compensation in the range of $500-$4,999 for serving as a KINECT-HD Steering Committee Member with Huntington Study Group. Dr. Adams has received personal compensation in the range of $500-$4,999 for serving as a ORCHESTRA-PD Steering Committee Member with Parkinson Study Group.
No disclosure on file
No disclosure on file
No disclosure on file
Christopher Tarolli, MD, FAAN (University of Rochester) Dr. Tarolli has received personal compensation for serving as an employee of University of Rochester. The institution of Dr. Tarolli has received research support from National Institutes of Health. The institution of Dr. Tarolli has received research support from Biogen. The institution of Dr. Tarolli has received research support from Neuron23. Dr. Tarolli has received personal compensation in the range of $500-$4,999 for serving as a Speaker, Committee Member with 好色先生. Dr. Tarolli has received personal compensation in the range of $500-$4,999 for serving as a Committee member with National Board of Medical Examiners. Dr. Tarolli has a non-compensated relationship as a Committee Member with 好色先生 that is relevant to AAN interests or activities.
No disclosure on file
No disclosure on file
Michael Curtis No disclosure on file
No disclosure on file
No disclosure on file
E. Ray Dorsey, MD, MBA (University of Rochester) Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Seelos Therapeutics. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eden McCallum, LLP. Dr. Dorsey has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech/Roche. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven Pharmaceuticals. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for WebMD. Dr. Dorsey has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BioSensics. Dr. Dorsey has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Mediflix. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevance. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kairos Cinema, LLC. Dr. Dorsey has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America Inc.. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for HanAll. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Dorsey has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Advarra. Dr. Dorsey has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medrhythms. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ANA. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for HMP 好色先生, LLP. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ADIVO Associates France. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for University of Toronto. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philadelphia Neurological Society. Dr. Dorsey has stock in Included Health. Dr. Dorsey has stock in Mediflix. Dr. Dorsey has stock in SemCap. Dr. Dorsey has stock in Synapticure. The institution of Dr. Dorsey has received research support from NIH/NINDS. The institution of Dr. Dorsey has received research support from Burroughs Wellcome . The institution of Dr. Dorsey has received research support from Michael J. Fox Foundation - Fox Insight. The institution of Dr. Dorsey has received research support from Michael J. Fox Foundation - Emerald. The institution of Dr. Dorsey has received research support from B. Thomas Golisano Foundation. The institution of Dr. Dorsey has received research support from Emerald Innovations, Inc.. The institution of Dr. Dorsey has received research support from Photopharmics Inc.. The institution of Dr. Dorsey has received research support from Averitas Pharma Inc.. The institution of Dr. Dorsey has received research support from DOD/Army Medical Research Acquisition Activity. The institution of Dr. Dorsey has received research support from NIH/NINDS.